13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05201638 (ClinicalTrials.gov) | January 12, 2022 | 13/12/2021 | Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2) | Multiple Sclerosis, Relapsing-Remitting | Drug: IMU-838 tablets;Drug: Placebo matching IMU-838 tablets | Immunic AG | NULL | Recruiting | 18 Years | 55 Years | All | 1050 | Phase 3 | United States;Armenia;Bosnia and Herzegovina;Estonia;India;Poland;Romania;Serbia;Turkey;Ukraine |
| 2 | NCT05134441 (ClinicalTrials.gov) | November 18, 2021 | 30/9/2021 | Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1) | Multiple Sclerosis | Drug: IMU-838 tablets;Drug: Placebo matching IMU-838 tablets | Immunic AG | NULL | Recruiting | 18 Years | 55 Years | All | 1050 | Phase 3 | Lithuania;Mexico;Moldova, Republic of;North Macedonia;Ukraine;United States;Albania;Bulgaria;Georgia;India |